BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.
Stocks · News reference
BeyondSpring's Subsidiary SEED Therapeutics Has Received FDA Orphan Drug Designation For ST-01156 For Treatment Of Neuroblastoma
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1149926
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — BeyondSpring Inc. (BYSI)
Filed: 2026-08-14 AccNo: 0001171843-26-005557 Size: 316 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report came out
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.